A nationwide shortage of BCG vaccines in the country leaves Kenyan newborns vulnerable to TB, a disease with a high ...

A new tuberculosis vaccine that self-destructs to enhance safety has shown promising results in macaque monkeys, providing ...

Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational ...

Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain ...

Scientists have developed a breakthrough mechanism that makes the intravenous Bacillus Calmette-Guérin (BCG) tuberculosis ...

Intravenous BCG vaccine with a built-in kill-switch was found to be at least as effective as regular tuberculosis vaccine in protecting monkeys against infection.

Kenya has completely run out of essential medical supplies—including HIV medicines, testing kits, and vaccines—putting ...

J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...

A self-destructing vaccine administered intravenously provides additional safety and protection against tuberculosis (TB) in macaque monkeys, suggests new University of Pittsburgh research published ...